why choose us

First received: May 03, 2023

Clinical Trial: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Glioblastoma, IDH-wildtype

Study Type: INTERVENTIONAL


Official Title: An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Brief Summary: The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

Read more